{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:01Z","timestamp":1787841001429,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"\n Background:<\/jats:title>\n Presbyopia, an age-related condition characterized by the gradual loss of near vision accommodation, affects a substantial portion of the global population. While Pilocarpine has demonstrated effectiveness in managing presbyopia, there is increasing interest in exploring combination therapies to enhance treatment efficacy and tolerability.<\/jats:p>\n <\/jats:sec>\n \n Purpose:<\/jats:title>\n To compare the efficacy and safety of 1% Pilocarpine monotherapy versus a combination of 1% Pilocarpine and 0.09% Bromfenac for the treatment of presbyopia over an 8-week period.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A prospective, randomized clinical trial was conducted involving presbyopic patients who were assigned to one of two treatment groups. Evaluations were performed to assess near visual acuity, accommodative function, patient satisfaction, safety, and compliance.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Both treatment groups showed significant improvements in near vision function. At the 8-week mark, 44.1% of patients in the Pilocarpine-only group and 78.6% of those in the combination therapy group achieved N6 near vision. The combination therapy group exhibited superior results in near point of accommodation (NPA) and accommodative amplitude (\n P<\/jats:italic>\n < 0.05). Patient satisfaction improved similarly in both groups. However, the combination therapy group reported fewer adverse events (1.8% vs. 11.9%,\n P<\/jats:italic>\n < 0.05) and higher treatment compliance (96.4% vs. 64.4%,\n P<\/jats:italic>\n < 0.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n While both treatment regimens effectively improved near vision in patients with presbyopia, the combination of Pilocarpine and Bromfenac demonstrated superior outcomes in terms of accommodative function, safety profile, patient compliance, and a reduced need for glasses. These results suggest that this combination therapy may offer a more effective pharmacological approach to the management of presbyopia.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1354_25","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:00:14Z","timestamp":1774519214000},"page":"492-498","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% Bromfenac"],"prefix":"10.4103","volume":"74","author":[{"given":"Anu","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merensoba T","family":"Imchen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Gangwar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahipal","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Dubey","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"R1-20260416","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.ophtha.2018.04.013","article-title":"Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: Systematic review, meta-analysis, and modelling","volume":"125","author":"Fricke","year":"2018","journal-title":"Ophthalmology"},{"key":"R2-20260416","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0042-6989(98)00283-1","article-title":"Biometric, optical and physical changes in the isolated human crystalline lens with age in relation to presbyopia","volume":"39","author":"Glasser","year":"1999","journal-title":"Vision Res"},{"key":"R3-20260416","first-page":"40","article-title":"Presbyopia: Prevalence, impact, and interventions","volume":"20","author":"Patel","year":"2007","journal-title":"Community Eye Health"},{"key":"R4-20260416","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0974-9233.124080","article-title":"Current management of presbyopia","volume":"21","author":"Papadopoulos","year":"2014","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R5-20260416","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3390\/jcm11051385","article-title":"Pharmacological treatment in presbyopia","volume":"11","author":"Grzybowski","year":"2022","journal-title":"J Clin Med"},{"key":"R6-20260416","first-page":"3","article-title":"Presbyopia: A new potential pharmacological treatment","volume":"1","author":"Benozzi","year":"2012","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"R7-20260416","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40123-018-0154-6","article-title":"Near vision improvement with the use of a new topical compound for presbyopia correction: A prospective, consecutive interventional non-comparative clinical study","volume":"8","author":"Vargas","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"R8-20260416","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2147\/OPTH.S476658","article-title":"Combination low-dose pilocarpine\/diclofenac sodium and pilocarpine alone for presbyopia: Results of a randomized phase 2b clinical trial","volume":"18","author":"Farid","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R9-20260416","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2147\/PPA.S46667","article-title":"Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: Safety, efficacy, and patient adherence","volume":"8","author":"Rajpal","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"R10-20260416","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2147\/OPTH.S208700","article-title":"Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: A review of published studies","volume":"13","author":"Schechter","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R11-20260416","doi-asserted-by":"crossref","first-page":"e000453","DOI":"10.1136\/bmjophth-2020-000453","article-title":"Patient-reported outcome measures in presbyopia: A literature review","volume":"5","author":"Sharma","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"key":"R12-20260416","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40662-016-0065-3","article-title":"Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia","volume":"3","author":"Abdelkader","year":"2016","journal-title":"Eye Vis (Lond)"},{"key":"R13-20260416","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40123-016-0050-x","article-title":"Pharmacological treatment of presbyopia by novel binocularly instilled eye drops: A pilot study","volume":"5","author":"Renna","year":"2016","journal-title":"Ophthalmol Ther"},{"key":"R14-20260416","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","article-title":"Nonsteroidal anti-inflammatory drugs in ophthalmology","volume":"55","author":"Kim","year":"2010","journal-title":"Surv Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1354_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:39:45Z","timestamp":1787837985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1354_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1354_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"2025-05-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}